Skip to main content
Clinical Trials/NCT01111422
NCT01111422
Unknown
Phase 4

A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis

Ewha Womans University1 site in 1 country66 target enrollmentMarch 2010

Overview

Phase
Phase 4
Intervention
N-acetylcysteine
Conditions
End-Stage Kidney Disease
Sponsor
Ewha Womans University
Enrollment
66
Locations
1
Primary Endpoint
Peritoneal membrane function
Last Updated
16 years ago

Overview

Brief Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of reactive oxygen species may be responsible for progressive membrane dysfunction. N-acetylcysteine (NAC)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model. In this study the researchers investigated the hypothesis that NAC protect peritoneal membrane damage.

Detailed Description

N-Acetylcysteine (NAC) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 1200 mg per day. Patients will be randomly assigned to NAC and control group and prescribed according to the protocol. At 2 and 6 month, Peritoneal equilibrium test (PET) will be performed with blood sampling.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
December 2011
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Maintenance peritoneal dialysis at least 3 months
  • Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information

Exclusion Criteria

  • Episode of peritonitis at least 3 months
  • Episodes of admission due to other disease at lease 3 months
  • Liver disease
  • Allergic history with N-acetylcysteine

Arms & Interventions

N-acetylcysteine

N-acetylcysteine in stable peritoneal dialysis patients

Intervention: N-acetylcysteine

Outcomes

Primary Outcomes

Peritoneal membrane function

Time Frame: 6 months

Changes in peritoneal membrane function (Δ D/Pcreatinine, ΔD/Purea) with peritoneal equilibrium test

Secondary Outcomes

  • Oxydative stress status(6 months)
  • Mesothelial cell transformation (Epithelial to Mesenchymal Transition)(6 month)
  • Residual renal function(6 month)
  • Peritoneal membrane function(2 months)

Study Sites (1)

Loading locations...

Similar Trials